Drug
Brivanib clinical trials
Also written BMS-582664.
- studies test it
- 21
- open now
- 0
- in phase 3
- 5
- first study started
- 2000
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 8
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 6
Bristol-Myers Squibb (14) · Gynecologic Oncology Group (2) · NCIC Clinical Trials Group (1) · Zai Lab (Shanghai) Co., Ltd. (1) · Abramson Cancer Center at Penn Medicine (1) · M.D. Anderson Cancer Center (1) · Hunan Cancer Hospital (1)
Often tested with
Tested in the same studies.
Cetuximab (2) · Irinotecan (2) · Sorafenib (1) · Niraparib (1)
Studies
Open first, then newest update. How each study uses brivanib is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular CancerCompletedPhase 2Bristol-Myers SquibbNCT00355238Written as brivanib (active)
- Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal CancerCompletedPhase 3NCIC Clinical Trials GroupNCT00640471Written as brivanib alaninate
- Brivanib Metastatic Renal Cell CarcinomaTerminatedPhase 2Abramson Cancer Center at Penn MedicineNCT01253668Written as Brivanib alaninate
- Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGFTerminatedPhase 2M.D. Anderson Cancer CenterNCT01367275Written as Brivanib
- Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCCCompletedPhase 3Bristol-Myers SquibbNCT00908752Written as Brivanib
- Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib TreatmentCompletedPhase 3Bristol-Myers SquibbNCT00825955Written as Brivanib
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedPhase 2Zai Lab (Shanghai) Co., Ltd.NCT03516071Written as Brivanib 800 mg, QD
- A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownPhase 1Hunan Cancer HospitalNCT03895788Written as Brivanib
- Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical CancerCompletedPhase 2Gynecologic Oncology GroupNCT01267253Written as Brivanib Alaninate
- Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedPhase 2Gynecologic Oncology GroupNCT00888173Written as Brivanib Alaninate
- First Line Hepato Cellular Carcinoma (HCC)CompletedPhase 3Bristol-Myers SquibbNCT00858871Written as Brivanib
- Phase I/II Combination With Irinotecan- ErbituxCompletedPhase 1/2Bristol-Myers SquibbNCT00594984Written as Brivanib
- Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib TreatmentTerminatedPhase 3Bristol-Myers SquibbNCT01108705Written as Brivanib
- Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesCompletedPhase 2Bristol-Myers SquibbNCT00633789Written as brivanib
- Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)CompletedPhase 1Bristol-Myers SquibbNCT01540461Written as Brivanib
- A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)CompletedPhase 1Bristol-Myers SquibbNCT00437437Written as Brivanib
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver DysfunctionCompletedPhase 1Bristol-Myers SquibbNCT00437424Written as Brivanib
- BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal MalignanciesCompletedPhase 1Bristol-Myers SquibbNCT00207051Written as Brivanib + Cetuximab
- Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) MalignanciesTerminatedPhase 1Bristol-Myers SquibbNCT00300027Written as BMS-582664
- A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)CompletedPhase 1Bristol-Myers SquibbNCT00435669Written as Brivanib
See all 21 studies that test brivanib →
Given in every arm · 2 — brivanib is usual care beside what is tested
- Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced CancersCompletedPhase 1Bristol-Myers SquibbNCT00798252Written as Brivanib alaninate
- Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)CompletedPhase 1Bristol-Myers SquibbNCT01046864Written as Brivanib
Codes
What other systems call brivanib · ClinicalTrials.gg INT004906
- MeSH (NLM) C509922brivanibOne source NLM
- UNII (FDA) DDU33B674IBRIVANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27075503brivanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C67040BrivanibOne source FDA
- DrugBank DB11958One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509922 | brivanib | One source NLM |
| UNII (FDA) | DDU33B674I | BRIVANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27075503 | brivanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C67040 | Brivanib | One source FDA |
| DrugBank | DB11958 | — | One source Wikidata |
Also registered as brivanib alaninate (UNII U2Y5OFN795).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.